ERBB2 and breast carcinoma: Our work is an updated systematic review and meta-analysis on relevant RCTs published after February 2019 (the literature search dated 15 June 2018) comparing TC and anthracycline-taxane-based chemotherapy in stages I–III, high-risk, HER2-negative breast cancer patients.